Friedreich’s Ataxia News and Research

RSS
Exercise has profound protective effect in mouse models of Friedreich's ataxia

Exercise has profound protective effect in mouse models of Friedreich's ataxia

New molecular mechanism can reverse genetic defect responsible for Friedreich's ataxia

New molecular mechanism can reverse genetic defect responsible for Friedreich's ataxia

C-Path and FARA announce launch of Friedreich's Ataxia Integrated Clinical Database

C-Path and FARA announce launch of Friedreich's Ataxia Integrated Clinical Database

UCLA researchers reveal reversibility of Friedreich's ataxia in mouse models

UCLA researchers reveal reversibility of Friedreich's ataxia in mouse models

Early intervention may be crucial to successful treatment of Friedreich's ataxia

Early intervention may be crucial to successful treatment of Friedreich's ataxia

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Riluzole ‘a candidate treatment’ for cerebellar ataxia

Riluzole ‘a candidate treatment’ for cerebellar ataxia

USF, FARA to jointly host scientific symposium on Friedreich's ataxia

USF, FARA to jointly host scientific symposium on Friedreich's ataxia

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

Scientists join patients to address Friedreich's Ataxia

Scientists join patients to address Friedreich's Ataxia

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Study discovers pathways that govern instability of GAA/TTC repeats

Study discovers pathways that govern instability of GAA/TTC repeats

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

FARA announces 2011 Ataxian Athlete Initiative grant recipients

FARA announces 2011 Ataxian Athlete Initiative grant recipients

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen first quarter total revenue increases 9% to $7,654,000

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.